These guidelines represent a GRADE-method revision of the recommendations produced by the Italian Society of Hemapheresis and Cell Manipulation (SIDEM) and the Italian Transplant Group for Bone Marrow Transplantation, Hematopoietic Stem Cells and Cell Therapy (GITMO) in 2013. Since 2013 several studies h...
Barosi, Giovanni;
Merlini, Giampaolo;
Atto, Billio;
Boccadoro, Mario;
Corradini, Paolo;
Marchetti, Monia;
Massaia, Massimo;
Tosi, Patrizia;
Palumbo, Antonio;
Cavo, Michele;
Tura, Sante.
In this project, we produced drug-specific recommendations targeting the use of new agents for multiple myeloma (MM). We used the GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) system which separates the judgments on quality of evidence from the judgment about strength of recom...
Protocolos de Quimioterapia Combinada Antineoplásica,
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación,
Ácidos Borónicos/uso terapéutico,
Bortezomib/uso terapéutico,
Hematología/legislación & jurisprudencia,
Hematología/métodos,
Lenalidomida/uso terapéutico,
Mieloma Múltiple/patología,
Clasificación del Tumor,
Pirazinas/administración & dosificación,
Sociedades Médicas/legislación & jurisprudencia,
Talidomida/uso terapéutico
Zinzani, Pier Luigi;
Marchetti, Monia;
Billio, Atto;
Barosi, Giovanni;
Carella, Angelo Michele;
Lazzarino, Mario;
Martelli, Maurizio;
Rambaldi, Alessandro;
Rigacci, Luigi;
Tarella, Corrado;
Vitolo, Umberto;
Tura, Sante.
By using the GRADE system, we updated the guidelines for management of follicular cell lymphoma issuedin 2006 from SIE, SIES, and GITMO group. We confirmed our recommendation to frontline chemoimmuno-therapy in patients with Stage III–IV disease and/or high tumor burden. Maintenance rituximab was alsor...
Anticuerpos Monoclonales,
Anticuerpos,
Anticuerpos Monoclonales de Origen Murino/uso terapéutico,
Antineoplásicos,
Esquema de Medicación,
Trasplante de Células Madre Hematopoyéticas,
Linfoma Folicular/patología,
Linfoma/terapia,
Estadificación de Neoplasias,
Rituximab,
Factores de Tiempo
